7 completed, 4 terminated, 3 unknown, 1 recruiting. 16 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Completed 7, Terminated 4, Unknown 3, Recruiting 1, Withdrawn 1 |
| Phase 2 | 6 | Completed 5, Unknown 1 |
Follow Adenomatous Polyps: new trials by email Literature Review of Adenomatous Polyps trials Research Report on Adenomatous Polyps
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis eRapa (encapsulated rapamycin), Placebo - Familial Adenomatous Polyposis (FAP) | Phase 3 | Recruiting | Rapamycin Holdings Inc. | 168 | 2025-07-18 | 2026-06-02 |
| Chemopreventive Effect of Combination of Celecoxib and Metformin in Patients With Familial Adenomatous Polyposis celecoxib monotherapy, celecoxib and metformin combination - Familial Adenomatous Polyposis | Phase 3 | Unknown | Yonsei University | 28 | 2024-08-13 | 2024-08-09 |
| Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis Eicosapentaenoic acid free fatty acid (EPA-FFA), Placebo - Familial Adenomatous Polyposis | Phase 3 | Unknown | S.L.A. Pharma AG | 204 | 2018-12-05 | 2024-04-25 |
| Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP) Eflornithine, Eflornithine Placebo, Sulindac 150 MG - Familial Adenomatous Polyposis | Phase 3 | Completed | Cancer Prevention Pharmaceuticals, Inc. | 171 | 2013-10-01 | 2021-06-08 |
| A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP) Eflornithine plus Sulindac, Eflornithine plus Placebo, Sulindac plus Placebo - Familial Adenomatous Polyposis | Phase 3 | Withdrawn | Cancer Prevention Pharmaceuticals, Inc. | 2011-03-01 | 2015-04-24 | |
| Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery rosuvastatin, placebo - Colorectal Cancer, Precancerous Condition | Phase 3 | Terminated | NSABP Foundation Inc | 406 | 2010-03-01 | 2023-08-16 |
| Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis Celecoxib, Ursodeoxycholic acid, Placebo - Familial Adenomatous Polyposis, Duodenal Neoplasms | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 37 | 2009-05-01 | 2013-05-16 |
| S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000 Vitamin E, Selenium, Vitamin E placebo - Colorectal Cancer, Precancerous Condition | Phase 3 | Completed | SWOG Cancer Research Network | 8094 | 2008-06-01 | 2019-12-16 |
| Chemoprevention of Colorectal Adenomas 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol), 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3), placebo to 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol) - Adenomatous Polyps | Phase 3 | Terminated | Colotech A/S | 350 | 2007-06-01 | 2020-09-03 |
| Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA Eicosapentanoic Acid (EPA), Endoscopy, Biopsies taken - Familial Adenomatous Polyposis Coli, FAP | Phase 2 / Phase 3 | Completed | S.L.A. Pharma AG | 58 | 2006-11-01 | 2014-08-22 |
| Effect of 2 Doses of EPA on Apoptosis and Cell Proliferation on Colon Mucosa Eicosapentaenoic Acid (EPA), Endoscopy, Biopsies taken - Adenomatous Polyps | Phase 2 / Phase 3 | Completed | S.L.A. Pharma AG | 120 | 2006-10-01 | 2008-10-17 |
| Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP) Celecoxib, Placebo - Adenomatous Polyposis Coli | Phase 3 | Terminated | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 106 | 2006-09-01 | 2021-02-21 |
| Selenium for Prevention of Adenomatous Colorectal Polyps Selenium - Colorectal Cancer, Adenomatous Colorectal Polyps | Phase 3 | Terminated | University of Arizona | 1621 | 2005-01-20 | 2019-09-24 |
| Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients Ursodeoxycholic acid, Placebo - Adenomatous Polyposis Coli, Familial | Phase 2 / Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 90 | 2004-10-01 | 2009-07-29 |
| Vitamin D/Calcium Polyp Prevention Study Calcium Carbonate, Vitamin D3, placebo - Colorectal Cancer, Polyps | Phase 2 / Phase 3 | Completed | Dartmouth-Hitchcock Medical Center | 2813 | 2004-07-01 | 2017-03-15 |
| Aspirin/Folate Prevention of Large Bowel Polyps Aspirin, Folate - Colorectal Cancer, Polyps | Phase 2 / Phase 3 | Completed | Dartmouth-Hitchcock Medical Center | 1121 | 1992-02-01 | 2020-03-13 |
Adenomatous Polyposis Coli (9) · Polyps (7) · Adenoma (5) · Colorectal Neoplasms (5) · Colonic Neoplasms (3) · Precancerous Conditions (3) · Hyperplasia (2) · Rectal Neoplasms (2) · Colonic Polyps (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Duodenal Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1)
Neoplasms (16) · Neoplasms by Histologic Type (16) · Neoplasms, Glandular and Epithelial (16) · Colonic Diseases (14) · Neoplasms by Site (14) · Digestive System Diseases (13) · Digestive System Neoplasms (13) · Gastrointestinal Diseases (13) · Gastrointestinal Neoplasms (13) · Intestinal Diseases (13) · Intestinal Neoplasms (13) · Adenoma (11) · Colorectal Neoplasms (9) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Intestinal Polyposis (9)
Celecoxib (3) · Aspirin (2) · Calcium Carbonate (2) · Colonoscopy (2) · Eflornithine (2) · Eicosapentaenoic Acid (2) · Endoscopy (2) · Selenium (2) · Sulindac (2) · Ursodeoxycholic Acid (2) · Calcitriol (1) · Cholecalciferol (1) · Clinical Chemistry Tests (1) · Docosahexaenoic Acids (1) · Folic Acid (1)
S.L.A. Pharma AG (3) · Cancer Prevention Pharmaceuticals, Inc. (2) · Dartmouth-Hitchcock Medical Center (2) · Assistance Publique - Hôpitaux de Paris (1) · Colotech A/S (1) · NSABP Foundation Inc (1) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1) · Radboud University Medical Center (1) · Rapamycin Holdings Inc. (1) · SWOG Cancer Research Network (1) · University of Arizona (1) · Yonsei University (1)
United States (9) · Italy (4) · United Kingdom (4) · Canada (3) · Netherlands (3) · Puerto Rico (3) · Spain (3) · Belgium (2) · Germany (2) · Czechia (1) · Denmark (1) · France (1) · Hong Kong (1) · Hungary (1) · Israel (1)
M. Peter Lance, MD (2) · Nicholas J West, MB BS FRCS (2) · Alfred M. Cohen, M.D. (1) · Bjorn WH van Heumen, MD (1) · Carol Burke, M.D. (1) · Ellen Kampman, Ph D (1) · Fokko M Nagengast, MD, Ph D (1) · Gary Shangold, MD (1) · Hans Raskov, M.D. (1) · James Church, M.D. (1) · John A Baron, MD, MSc (1) · John A. Baron, MD (1) · Luigi Ricciardiello, MD (1) · Norman Wolmark, MD (1)
PMID 34289971, PMID 12621133, PMID 17551129, PMID 18378608, PMID 18541589, PMID 19923375, PMID 20348368, PMID 20685491, PMID 21899713, PMID 23060037, PMID 23919274, PMID 24014734, PMID 24245549, PMID 25070320, PMID 25329821, PMID 26404953, PMID 26465985, PMID 27094489, PMID 27474021, PMID 27519183, PMID 27683872, PMID 27978548, PMID 28218420, PMID 28767463, PMID 29496722, PMID 30899530, PMID 31263057, PMID 31401653, PMID 32905675, PMID 33022713, PMID 34261858, PMID 34762658, PMID 35815403, PMID 36701139
P01CA041108 (1), P30CA023074 (1), R01CA098286 (1), U10CA037429 (1)